ENDRA Files S-4 for Reverse Merger with Noble Africa: ASP Isotopes to Control 98.8% of Voting Power

summarizeSummary

ENDRA filed its S-4 registration statement for the proposed reverse merger with Noble Africa, a subsidiary of ASP Isotopes. The filing reveals ASP Isotopes will control 98.8% of voting power, existing ENDRA stockholders will hold only 0.3%, and the deal includes a $50 million Noble Investment and a potential reverse stock split.

check_boxKey Events · M&A and Partnerships · NDRA

• Reverse Merger with Noble Africa

  Merger Sub will merge into Noble Africa, with Noble Africa surviving as a wholly owned subsidiary of ENDRA. ENDRA will be renamed '4K Resources Inc.' and trade under symbol 'LHE' on Nasdaq.

• ASP Isotopes to Control 98.8% of Voting Power

  Dual-class structure gives Class B Common Stock 10 votes per share. ASP Isotopes expected to hold 100% of Class B shares, representing 98.8% of combined voting power. Existing ENDRA stockholders diluted to approximately 0.3%.

• $50 Million Noble Investment

  Noble Africa selling 4,594,216 Class A Units and/or pre-funded warrants to institutional investors and 3,054,185 Class B Units to ASP Isotopes at $6.57 per unit for approximately $50 million gross proceeds.

• No Fairness Opinion; Advisor Conflict

  ENDRA did not obtain a third-party fairness opinion. Financial advisor Lucid Capital Markets will receive 450,000 Class A shares plus warrants for 700,000 shares at $7.00, while also serving as placement agent for the Noble Investment.

auto_awesomeAnalysis · NDRA · Industrial Applications And Services

This S-4 marks the first complete public disclosure of the merger terms, and it reveals a stark power shift: ASP Isotopes will control approximately 98.8% of the combined company's voting power through a dual-class structure with 10 votes per share for Class B stock. Existing ENDRA stockholders are diluted to roughly 0.3% of voting power. The filing also discloses that ENDRA did not obtain a fairness opinion, that its financial advisor Lucid has a conflict of interest (being compensated with combined company securities while also serving as placement agent for the Noble Investment), and that Renergen — the operating business being acquired — has a going concern warning, covenant non-compliance, and $113.8 million in borrowings. The merger is effectively a reverse takeover where ENDRA's medical device business becomes a shell for Renergen's helium and LNG operations. Stockholders face a binary choice: approve the merger or risk liquidation, as the filing states ENDRA has limited ability to continue operations if the merger fails.